Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that a clinical study featuring 68Ga-Trivehexin (68Ga-RAD 301), conducted by Dr. Rehm and colleagues from the Technische Universität Dresden, has now been…
Lightning Minerals (L1M or the Company) is delighted to announce the discovery of spodumene within a lithium bearing pegmatite…
Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress…
Gunnison Copper (TSX:GCU,OTCQB:EXMGF) is shifting its development strategy for the Gunnison copper project in Arizona, US, laying out plans…
Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder. Click here…
Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF) (‘Alvopetro’ or the ‘Company’) announces the annual rolling grants of long-term incentive…
The S&P/TSX Venture Composite Index (INDEXTSI:JX) fell 2.63 percent on the week to close at 591.22 on Friday (November…
Cobalt market watchers are warning that a near-term resurgence in prices and demand may not occur. Cobalt prices have…
Syntheia Corp. (‘Syntheia’ or the ‘Company’) (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative…